Last updated on May 2018

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis


Brief description of study

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.

Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis.

CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Clinical Study Identifier: NCT02158858

Contact Investigators or Research Sites near you

Start Over

Debbie Johnson

Massachusetts General Hospital
Boston, MA United States
  Connect »

Debbie Johnson

Memorial Sloan-Kettering Cancer Center
New York, NY United States
  Connect »

Debbie Johnson

University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, PA United States
  Connect »

Wael Harb, MD

Horizon Oncology Center
Lafayette, IN United States
  Connect »

Marina Kremyanskya, MD PhD

Icahn School of Medicine at Mount Sinai
New York, NY United States
  Connect »

Nashat Gabrail, MD

Gabrail Cancer Center
Canton, OH United States
  Connect »